MOMENTUM

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
100 patients (estimated)
Tags
IKZF1/3
Trial Type
Treatment
Last Update
SparkCures ID
2197
NCT Identifier
NCT07284758

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.